Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
about
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Tofacitinib for the treatment ...... cebo-controlled phase 3 trial.
@en
type
label
Tofacitinib for the treatment ...... cebo-controlled phase 3 trial.
@en
prefLabel
Tofacitinib for the treatment ...... cebo-controlled phase 3 trial.
@en
P2093
P2860
P50
P356
P1476
Tofacitinib for the treatment ...... acebo-controlled phase 3 trial
@en
P2093
Anna M Tallman
Hideshi Torii
Hironobu Ihn
Isao Kawaguchi
Makoto Nagaoka
Mihoko Kobayashi
Naoki Isogawa
Yukiko Tomochika
P2860
P304
P356
10.1111/1346-8138.13956
P577
2017-07-17T00:00:00Z